Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/BCAS3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BCAS3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BCAS3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/BCAS3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BCAS3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/BCAS3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BCAS3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000704415 | Prostate | Tumor | cell-substrate junction assembly | 43/3246 | 95/18723 | 2.33e-10 | 1.34e-08 | 43 |
GO:005122218 | Prostate | Tumor | positive regulation of protein transport | 97/3246 | 303/18723 | 2.67e-10 | 1.48e-08 | 97 |
GO:005149517 | Prostate | Tumor | positive regulation of cytoskeleton organization | 78/3246 | 226/18723 | 3.05e-10 | 1.65e-08 | 78 |
GO:003158916 | Prostate | Tumor | cell-substrate adhesion | 109/3246 | 363/18723 | 1.41e-09 | 6.71e-08 | 109 |
GO:000716317 | Prostate | Tumor | establishment or maintenance of cell polarity | 74/3246 | 218/18723 | 2.00e-09 | 8.86e-08 | 74 |
GO:003238817 | Prostate | Tumor | positive regulation of intracellular transport | 70/3246 | 202/18723 | 2.01e-09 | 8.86e-08 | 70 |
GO:015011616 | Prostate | Tumor | regulation of cell-substrate junction organization | 34/3246 | 71/18723 | 2.86e-09 | 1.18e-07 | 34 |
GO:001081018 | Prostate | Tumor | regulation of cell-substrate adhesion | 73/3246 | 221/18723 | 9.68e-09 | 3.62e-07 | 73 |
GO:009013217 | Prostate | Tumor | epithelium migration | 105/3246 | 360/18723 | 1.57e-08 | 5.62e-07 | 105 |
GO:009013017 | Prostate | Tumor | tissue migration | 106/3246 | 365/18723 | 1.73e-08 | 6.10e-07 | 106 |
GO:001063117 | Prostate | Tumor | epithelial cell migration | 104/3246 | 357/18723 | 1.97e-08 | 6.91e-07 | 104 |
GO:009031614 | Prostate | Tumor | positive regulation of intracellular protein transport | 57/3246 | 160/18723 | 2.01e-08 | 7.03e-07 | 57 |
GO:000166718 | Prostate | Tumor | ameboidal-type cell migration | 130/3246 | 475/18723 | 2.36e-08 | 8.09e-07 | 130 |
GO:005189315 | Prostate | Tumor | regulation of focal adhesion assembly | 31/3246 | 66/18723 | 2.52e-08 | 8.33e-07 | 31 |
GO:009010915 | Prostate | Tumor | regulation of cell-substrate junction assembly | 31/3246 | 66/18723 | 2.52e-08 | 8.33e-07 | 31 |
GO:004804114 | Prostate | Tumor | focal adhesion assembly | 36/3246 | 87/18723 | 1.15e-07 | 3.01e-06 | 36 |
GO:000195214 | Prostate | Tumor | regulation of cell-matrix adhesion | 47/3246 | 128/18723 | 1.20e-07 | 3.14e-06 | 47 |
GO:003166719 | Prostate | Tumor | response to nutrient levels | 127/3246 | 474/18723 | 1.27e-07 | 3.28e-06 | 127 |
GO:001063217 | Prostate | Tumor | regulation of epithelial cell migration | 85/3246 | 292/18723 | 3.91e-07 | 8.63e-06 | 85 |
GO:003432915 | Prostate | Tumor | cell junction assembly | 113/3246 | 420/18723 | 4.94e-07 | 1.07e-05 | 113 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCAS3 | SNV | Missense_Mutation | novel | c.410N>G | p.Gln137Arg | p.Q137R | Q9H6U6 | protein_coding | tolerated(0.27) | benign(0.093) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BCAS3 | SNV | Missense_Mutation | rs755073133 | c.68N>A | p.Arg23His | p.R23H | Q9H6U6 | protein_coding | deleterious(0.04) | probably_damaging(0.937) | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
BCAS3 | SNV | Missense_Mutation | | c.2038N>A | p.Asp680Asn | p.D680N | Q9H6U6 | protein_coding | tolerated(0.07) | benign(0.073) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
BCAS3 | SNV | Missense_Mutation | novel | c.1331N>C | p.Arg444Pro | p.R444P | Q9H6U6 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-HN-A2OB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
BCAS3 | insertion | Frame_Shift_Ins | novel | c.2016_2017insTGGAATCATATAATATGTGACCTTTTGTGTCTGG | p.His673TrpfsTer52 | p.H673Wfs*52 | Q9H6U6 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
BCAS3 | SNV | Missense_Mutation | novel | c.2335N>A | p.Asp779Asn | p.D779N | Q9H6U6 | protein_coding | tolerated(0.09) | possibly_damaging(0.642) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BCAS3 | SNV | Missense_Mutation | rs759264893 | c.2318N>T | p.Thr773Met | p.T773M | Q9H6U6 | protein_coding | deleterious(0.02) | benign(0.401) | TCGA-C5-A1BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
BCAS3 | SNV | Missense_Mutation | novel | c.2158G>A | p.Glu720Lys | p.E720K | Q9H6U6 | protein_coding | deleterious(0.01) | possibly_damaging(0.879) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
BCAS3 | SNV | Missense_Mutation | | c.1755N>A | p.Phe585Leu | p.F585L | Q9H6U6 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-4N-A93T-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | SD |
BCAS3 | SNV | Missense_Mutation | rs377752373 | c.583N>T | p.Arg195Trp | p.R195W | Q9H6U6 | protein_coding | deleterious(0) | possibly_damaging(0.736) | TCGA-A6-5660-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |